Broadly Enabling Technology: The HypoSpray® technology presents a paradigm shift in transdermal delivery of drugs, away from small dose – small molecule therapies and limited applications to drugs that require larger bio-available doses for efficacy. As the company’s technology can accommodate large molecules, management believes it has the potential to deliver up to 70% of the drugs listed in the Physician Pharmaceutical Guide. The platform enables delivery of most pharmaceutical active ingredients in a pleasant, easy-to-use product with nearly instant, direct, absorption into the blood system. By-passing directly into the blood compartment, the stomach and gut are protected from the effects of processing and metabolizing what is essentially a foreign substance, and virtually eliminating stomach discomfort and concerns with taking medicine with meals or avoiding certain beverages or foods. The smaller dose of drug used in the HypoSpray® formula renders any drug normally taken by mouth safer by reducing toxicity, side effects and the potential for drug interactions. Technological Integration is Proven: The flexible, broadly enabling nature of the platform technology has been proven safe and effective in several studies, which have been published in peer-reviewed journals, and have demonstrated superiority of HypoSpray® systems over the market leaders, thereby minimizing the risk of technological change, while maximizing the product’s attractiveness over existing market competition.